Clinical Trials Logo

Filter by:
NCT ID: NCT06229340 Recruiting - Lung Cancer Clinical Trials

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

N??-RAS
Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.

NCT ID: NCT06226857 Recruiting - Clinical trials for Colorectal Neoplasms

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

CRC01
Start date: January 17, 2024
Phase: Phase 3
Study type: Interventional

Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or cetuximab) based on RAS/BRAF wild-type data, according to clinical guidelines. The BC cohort begins FOLFOX chemotherapy and simultaneously undergoes extensive molecular genetic profiling. Further, the BC cohort, depending on the profile, is divided into cohort B - patients without changes in alternative oncogenes, and cohort C - with changes in alternative oncogenes. The expected cohort ratio is 3:1 (~120 and ~40 patients). Cohort B begins to receive anti-EGFR therapy in addition to chemotherapy, and the potentially resistant cohort C continues to receive chemotherapy alone or begins to receive bevacizumab if there are no contraindications.

NCT ID: NCT06223945 Active, not recruiting - Clinical trials for COVID-19 (Coronavirus Disease 2019)

Thrombohemorrhagic Complications of COVID-19

Start date: January 12, 2024
Phase: N/A
Study type: Interventional

The nature of the planned study: The topic is of an applied nature and is aimed at improving the results of comprehensive treatment of patients with COVID-19, the course of whose disease was complicated by thrombotic or hemorrhagic catastrophes. It is planned to analyze the results of treatment of this category of patients based on the work of several centers that provided surgical care to patients with COVID-19 during the pandemic (8 cities). As a result of the analysis, it is planned to develop algorithms for the prevention and treatment of thrombotic and hemorrhagic complications in patients with COVID-19. The proposed study will be multicenter, cohort, retrospective. The purpose of the study: Improvement of treatment results in COVID-19 patients with thrombotic or hemorrhagic complications Scientific novelty: For the first time, as a result of a multicenter study, it is expected to identify the most effective approach to the treatment and prevention of thrombotic and hemorrhagic complications in patients with COVID-19. For the first time, it is planned to develop and put into practice algorithms for the application of the most effective methods of treatment and prevention of thrombohemorrhagic complications of COVID-19.

NCT ID: NCT06222801 Recruiting - Oncology Clinical Trials

The 1st Tumor CytokinoTherapy Database (TCTD-1)

Start date: September 19, 2022
Phase:
Study type: Observational

Predicting the response of patients diagnosed with cancer to cytokinotherapy is essential to guide anti-tumor therapy complex strategy and subsequent adjuvant approach. Cytokinotherapy is a cost-effective, well-known available method of therapy for the patients with tumors. The objective response possibly correlates to the tumor's size, aggressiveness, age, and other primary factors. Multifactor analysis requires a large amount of data. Therefore, the investigators created the first database aimed to collect data concerning the patients with cancer and the clinical outcomes of cytokinogenetic therapy. The acquired data must be processed to detect the key factors effecting the outcomes. Cytokinotherapy is a universal therapeutic approach, although we lack information that would help to personalize it and reduce the rate of progression. The main goal is to find the relationship between initial patients' characteristics and effectiveness of cytokinotherapy for early risks detection. The predictive models that could be elaborated from the TCTD-1 analysis will complement knowledge of cytokinotherapy rationale. Predicting survival or other significant clinical criteria using TCTD-1 analysis results would greatly benefit the cancer patients' management.

NCT ID: NCT06222645 Recruiting - Perfusion Clinical Trials

PPG vs. ICG in Gastrointestinal Resections

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

In this study, gastrointestinal anastomoses are examined with imaging Photoplethysmography and after this the investigators use the Standard Routine ICG-Imaging. At the end, both methods will be compared.

NCT ID: NCT06221826 Completed - Clinical trials for Ischemic Stroke, Acute

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

Start date: April 17, 2023
Phase: Phase 4
Study type: Interventional

The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

NCT ID: NCT06221696 Completed - Clinical trials for Overweight and Obesity

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

PWR-FAST
Start date: June 12, 2023
Phase: N/A
Study type: Interventional

This randomized, double-blind, placebo-controlled trial titled "Preventing Weight Regain Post-Semaglutide Treatment with Active Fiber Supplement (Soloways)" evaluated the efficacy of an active fiber supplement in preventing weight regain post-Semaglutide treatment. Participants were adults aged 18-65, with a history of obesity or overweight, and had completed a Semaglutide course. The study involved 160 participants, equally divided into two groups: one receiving the active fiber supplement (glucomannan, inulin, and psyllium) and the other a placebo, both taken 30 minutes before each main meal for 180 days. Co-primary endpoints were the percentage of weight regain from baseline to day 180 and metabolic health markers (blood glucose levels, HbA1c, lipid profile, blood pressure). Secondary endpoints included changes in BMI, body composition, and appetite assessment using VAS ratings and the Control of Eating Questionnaire (CoEQ). Participants also adhered to a reduced-calorie diet and increased physical activity, with all standard assays performed in a central laboratory. The study's objective was to determine the supplement's effectiveness in enhancing satiety, improving digestive health, and thus better managing weight compared to a placebo

NCT ID: NCT06215300 Recruiting - Clinical trials for to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Start date: December 1, 2022
Phase:
Study type: Observational

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

NCT ID: NCT06215196 Completed - Clinical trials for Overweight and Obesity

Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

ESSENCE
Start date: April 14, 2023
Phase: N/A
Study type: Interventional

This clinical trial investigated the combined effects of Semaglutide and a fiber supplement (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity. Participants, aged 18-65 with a BMI ≥30 or ≥27 with comorbidities, were randomized into two groups: one receiving Semaglutide with active fiber supplements and the other with Semaglutide and placebo, over a 180-day period. Key endpoints included percentage change in body weight, BMI, body composition, safety, and appetite control, with a focus on evaluating the additive effects of dietary fibers in enhancing Semaglutide's efficacy.

NCT ID: NCT06213610 Recruiting - Bioequivalence Clinical Trials

Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions

Start date: January 9, 2024
Phase: Phase 1
Study type: Interventional

This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.